Holen Sie sich die Stockscreener-App
11.41
2.81%
-0.33
Handel nachbörslich:
11.19
-0.22
-1.93%
Schlusskurs vom Vortag:
$11.74
Offen:
$11.8
24-Stunden-Volumen:
487.37K
Relative Volume:
0.70
Marktkapitalisierung:
$814.79M
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-3.9481
EPS:
-2.89
Netto-Cashflow:
$23.50M
1W Leistung:
-1.55%
1M Leistung:
-9.73%
6M Leistung:
+51.93%
1J Leistung:
-27.74%
1-Tages-Spanne:
$11.14
$11.81
1-Wochen-Bereich:
$11.12
$11.90
52-Wochen-Spanne:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
11.41 | 838.36M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Earnings Beat: Is Xencor Inc stock showing strong momentumDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Big Money Moves: What is the Moat Score of Xencor Inc2025 Momentum Check & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Swings: Can TACOU be recession proofTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
Aug Movers: Is The Shyft Group Incs growth already priced inJuly 2025 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
Understanding the Setup: (XNCR) and Scalable Risk - Stock Traders Daily
Will Xencor Inc. stock rally after Fed decisionsProfit Target & Consistent Growth Equity Picks - mfd.ru
What hedge funds are buying Xencor Inc.July 2025 Setups & Free High Return Stock Watch Alerts - mfd.ru
Will Xencor Inc. stock go up in YEAR2025 Market Sentiment & Community Verified Trade Alerts - mfd.ru
Is Xencor Inc. affected by consumer sentimentJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - mfd.ru
The Truth About Xencor Inc: Why Biotech Degens Suddenly Care About XNCR - AD HOC NEWS
Meme Stocks: Is Xencor Inc a top pick in the sector2025 Market Outlook & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Reactions: Can Xencor Inc expand its profit margins2025 Major Catalysts & Accurate Trade Setup Notifications - baoquankhu1.vn
Xencor, Inc. (XNCR) Investor Outlook: A Biotech Stock With A 148% Potential Upside - DirectorsTalk Interviews
How do insiders feel about Xencor Inc.2025 Geopolitical Influence & Technical Entry and Exit Tips - mfd.ru
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate - simplywall.st
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (NASDAQ:XNCR) Stock Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Can Xencor Inc. expand its profit margins2025 Top Gainers & Weekly Breakout Watchlists - mfd.ru
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector - Yahoo Finance
EV Market: Does Xencor Inc stock reflect fundamentalsMarket Trend Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet? - 富途牛牛
The Technical Signals Behind (XNCR) That Institutions Follow - Stock Traders Daily
Truist Securities reiterates Buy rating on Xencor stock amid TL1A momentum - Investing.com Australia
Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Bear Alert: Is Xencor Inc impacted by rising rates2025 Market Outlook & Safe Entry Point Identification - baoquankhu1.vn
Xencor’s Financial Runway Supports Ambitious Clinical Pipeline - AD HOC NEWS
Update Report: Can Xencor Inc stock outperform in a bear market2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Xencor, Inc. (XNCR) Stock Analysis: Unlocking a 132.90% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage - Finviz
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Precision Trading with Xencor Inc. (XNCR) Risk Zones - Stock Traders Daily
Contrasting NRx Pharmaceuticals (NASDAQ:NRXP) & Xencor (NASDAQ:XNCR) - Defense World
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - sharewise.com
Xencor, Inc. (XNCR) Stock Analysis: A Biotech Contender With 119.93% Potential Upside - DirectorsTalk Interviews
Activity Recap: Is Xencor Inc impacted by rising ratesQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative? - Yahoo Finance
Market Catalysts: What is the target price for Xencor Inc stockMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SG Americas Securities LLC Takes Position in Xencor, Inc. $XNCR - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones - Yahoo Finance
Navigating the Valuation Gap in Xencor Shares - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Down 7.1%Here's Why - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – Time to Sell? - Defense World
Merger Talk: What hedge fund activity signals for Xencor Inc stockJuly 2025 Action & Accurate Intraday Trade Tips - Bộ Nội Vụ
Performance Recap: Can Xencor Inc stock outperform in a bear marketMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
ImmunityBio, Xencor Drugs Win E.U. Nods - labusinessjournal.com
Xencor's Clinical Milestone Paves Way for Potential Revaluation () - aktiencheck.de
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Xencor, Inc.Common Stock (NQ: XNCR - FinancialContent
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):